Health
AstraZeneca's experimental lung drug cuts COPD flare-ups in late-stage trials
AstraZeneca's experimental injectable drug tozorakimab reduced COPD flare-ups by 30% in two clinical trials, STAT reports.
The short version
- AstraZeneca announced that late-stage trials of its experimental injectable drug tozorakimab reduced COPD exacerbations by approximately 30% across participants over one year.[STAT]
- The trials enrolled patients ineligible for other emerging COPD treatments, potentially providing AstraZeneca access to an exclusive market segment.[STAT]
- Company officials and market analysts project billions in annual revenue if regulators approve the treatment for COPD and additional conditions.[STAT]
Key facts
- Data from two late-stage trials showed AstraZeneca's tozorakimab reduced COPD exacerbations by approximately 30% across all patients over one year.[STAT]
- The findings were presented at the European Respiratory Society conference in Barcelona and published in the New England Journal of Medicine.[STAT]
- The Phase 3 trials included participants ineligible for other newer therapies, which could give AstraZeneca a dedicated market segment.[STAT]
- AstraZeneca and financial analysts estimate the drug could generate billions of dollars annually if granted regulatory approval.[STAT]
What remains uncertain
- Whether tozorakimab will secure regulatory approval for COPD or other indications remains pending.[STAT]
Sources
Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.